4.2 Article

Natalizumab as a Disease-Modifying Therapy in Chronic Inflammatory Demyelinating Polyneuropathy - A Report of Three Cases

Journal

EUROPEAN NEUROLOGY
Volume 73, Issue 5-6, Pages 294-302

Publisher

KARGER
DOI: 10.1159/000381767

Keywords

Natalizumab; CIDP; Immune-mediated neuropathy; VLA4; VCAM1; Blood-nerve barrier

Ask authors/readers for more resources

Background: Several treatments are available to treat the immune-mediated chronic inflammatory demyelinating polyneuropathy (CIDP). Among these treatments, intravenous immunoglobulins, corticosteroids and plasma exchanges are validated and widely used. A few immunosuppressive drugs have been tried, but they had little efficiency. Methods: We describe three CIDP patients treated by Natalizumab (acting against cellular adhesion and T-cell migration) after a failure of the validated treatments. Results: We observed a long-term improvement in one patient, a dramatic improvement over a significant duration in another patient and stabilization in the last one. Conclusion: This open label study provides evidence for the value of Natalizumab as second-line treatment for individual patients with a high dependency on waning efficacy of first-line therapies. CIDP is characterized by heterogeneity of clinical phenotypes, electrophysiological and pathological features, and various variable courses types of evolution. The different responses to drugs of our patients are consistent with some reported cases and may reflect the spectrum of lesional mechanisms and the molecular dysfunctions in CIDP. (C) 2015 S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Genetics & Heredity

Too many numbers and complexity: time to update the classifications of neurogenetic disorders?

Jean-Michel Vallat, Cyril Goizet, Laurent Magy, Stephane Mathis

JOURNAL OF MEDICAL GENETICS (2016)

Article Clinical Neurology

Simultaneous Quantification of Unmyelinated Nerve Fibers in Sural Nerve and in Skin

Mathilde Duchesne, Laurent Magy, Laurence Richard, Pierre Ingrand, Jean-Philippe Neau, Stephane Mathis, Jean-Michel Vallat

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2016)

Letter Clinical Neurology

Reasons Charcot-Marie-Tooth disease due to mutations in the MME gene should not be named AR-CMT2T

Stephane Mathis, Cyril Goizet, Meriem Tazir, Laurent Magy, Jean-Michel Vallat

ANNALS OF NEUROLOGY (2016)

Review Clinical Neurology

The therapeutic potential of renin angiotensin aldosterone system (RAAS) in chronic pain: from preclinical studies to clinical trials

Flavien Bessaguet, Laurent Magy, Alexis Desmouliere, Claire Demiot

EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)

Review Clinical Neurology

Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies

Jean-Michel Vallat, Laurent Magy, Jonathan Ciron, Philippe Corcia, Gwendal Le Masson, Stephane Mathis

EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)

Review Immunology

Novel immunotherapeutic strategies in chronic inflammatory demyelinating polyneuropathy

Stephane Mathis, Jean-Michel Vallat, Laurent Magy

IMMUNOTHERAPY (2016)

Article Clinical Neurology

Long-term safety and efficacy of teriflunomide Nine-year follow-up of the randomized TEMSO study

Paul O'Connor, Giancarlo Comi, Mark S. Freedman, Aaron E. Miller, Ludwig Kappos, Jean-Pierre Bouchard, Christine Lebrun-Frenay, Jan Mares, Myriam Benamor, Karthinathan Thangavelu, Jinjun Liang, Philippe Truffinet, Victoria J. Lawson, Jerry S. Wolinsky

NEUROLOGY (2016)

Article Clinical Neurology

Comparative efficacy of fingolimod vs natalizumab A French multicenter observational study

Laetitia Barbin, Chloe Rousseau, Natacha Jousset, Romain Casey, Marc Debouverie, Sandra Vukusic, Jerome De Seze, David Brassat, Sandrine Wiertlewski, Bruno Brochet, Jean Pelletier, Patrick Vermersch, Gilles Edan, Christine Lebrun-Frenay, Pierre Clavelou, Eric Thouvenot, Jean-Philippe Camdessanche, Ayman Tourbah, Bruno Stankoff, Abdullatif Al Khedr, Philippe Cabre, Caroline Papeix, Eric Berger, Olivier Heinzlef, Thomas Debroucker, Thibault Moreau, Olivier Gout, Bertrand Bourre, Alain Creange, Pierre Labauge, Laurent Magy, Gilles Defer, Yohann Foucher, David A. Laplaud

NEUROLOGY (2016)

Article Clinical Neurology

Congenital hypomyelinating neuropathy due to the association of a truncating mutation in PMP22 with the classical HNPP deletion

Maxime Jouaud, Pierre-Marie Gonnaud, Laurence Richard, Philippe Latour, Elisabeth Ollagnon-Roman, Franck Sturtz, Stephane Mathis, Laurent Magy, Jean-Michel Vallat

NEUROMUSCULAR DISORDERS (2016)

Correction Genetics & Heredity

An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A (vol 9, 199, 2014)

Shahram Attarian, Jean-Michel Vallat, Laurent Magy, Benoit Funalot, Pierre-Marie Gonnaud, Arnaud Lacour, Yann Pereon, Odile Dubourg, Jean Pouget, Joelle Micallef, Jerome Franques, Marie-Noelle Lefebvre, Karima Ghorab, Mahmoud Al-Moussawi, Vincent Tiffreau, Marguerite Preudhomme, Armelle Magot, Laurene Leclair-Visonneau, Tanya Stojkovic, Laura Bossi, Philippe Lehert, Walter Gilbert, Viviane Bertrand, Jonas Mandel, Aude Milet, Rodolphe Hajj, Lamia Boudiaf, Catherine Scart-Gres, Serguei Nabirotchkin, Mickael Guedj, Ilya Chumakov, Daniel Cohen

ORPHANET JOURNAL OF RARE DISEASES (2016)

Article Multidisciplinary Sciences

Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional Observational Study

Celine Dogan, Marie De Antonio, Dalil Hamroun, Hugo Varet, Marianne Fabbro, Felix Rougier, Khadija Amarof, Marie-Christine Arne Bes, Anne-Laure Bedat-Millet, Anthony Behin, Remi Bellance, Francoise Bouhour, Celia Boutte, Francois Boyer, Emmanuelle Campana-Salort, Francoise Chapon, Pascal Cintas, Claude Desnuelle, Romain Deschamps, Valerie Drouin-Garraud, Xavier Ferrer, Helene Gervais-Bernard, Karima Ghorab, Pascal Laforet, Armelle Magot, Laurent Magy, Dominique Menard, Marie-Christine Minot, Aleksandra Nadaj-Pakleza, Sybille Pellieux, Yann Pereon, Marguerite Preudhomme, Jean Pouget, Sabrina Sacconi, Guilhem Sole, Tanya Stojkovich, Vincent Tiffreau, Andoni Urtizberea, Christophe Vial, Fabien Zagnoli, Gilbert Caranhac, Claude Bourlier, Gerard Riviere, Alain Geille, Romain K. Gherardi, Bruno Eymard, Jack Puymirat, Sandrine Katsahian, Guillaume Bassez

PLOS ONE (2016)

Article Clinical Neurology

Classifications of neurogenetic diseases: An increasingly complex problem

J-M Vallat, C. Goizet, M. Tazir, P. Couratier, L. Magy, S. Mathis

REVUE NEUROLOGIQUE (2016)

Review Clinical Neurology

The therapeutic potential of renin angiotensin aldosterone system (RAAS) in chronic pain: from preclinical studies to clinical trials

Flavien Bessaguet, Laurent Magy, Alexis Desmouliere, Claire Demiot

EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)

Review Clinical Neurology

Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies

Jean-Michel Vallat, Laurent Magy, Jonathan Ciron, Philippe Corcia, Gwendal Le Masson, Stephane Mathis

EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)

Article Biochemistry & Molecular Biology

Early Diagnosis in Cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome (CANVAS) by Focusing on Major Clinical Clues: Beyond Ataxia and Vestibular Impairment

Laurent Magy, Pauline Chazelas, Laurence Richard, Nathalie Deschamps, Simon Frachet, Jean-Michel Vallat, Corinne Magdelaine, Frederic Favreau, Flavien Bessaguet, Anne-Sophie Lia, Mathilde Duchesne

Summary: CANVAS is a rare disorder characterized by late-onset ataxia and autosomal recessive inheritance. This study investigated eight patients with sensory neuropathy and/or an unexplained cough who showed symptoms of CANVAS, emphasizing the importance of early diagnosis. The findings reveal that chronic cough and neuropathic pain can be significant impairments in these patients, suggesting the need for early recognition to avoid unnecessary immunotherapy.

BIOMEDICINES (2022)

No Data Available